A phase II study of Velcade (bortezomib-PS341) in the treatment of patients over 18 years with Ph+ (Philadelphia chromosome positive) leukemia [i.e., chronic myeloid leukaemia, acute lymphoblastic leukaemia]
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Bortezomib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 21 Nov 2008 Status changed from recruiting to completed.
- 23 Aug 2007 New trial record.